Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation

Table 3 Conversion from IV to IM HBIG for prevention of HBV recurrence after LT

Authors	Patients (n)	DNA+ prior to LT (%)	Pretransplant LAM therapy (%)	Duration of pretransplant LAM therapy (mean mo)	DNA+ at LT (%)	Prophylactic protocol after LT	Follow-up (mean mo)	Recurrence (%)
Ferretti et al[94]	23	48	48	NA	13	LAM + HBIG1	20	3.6
Han et al[95]	59	NA	59	7.7	8	LAM + HBIG2	35	03, 24
Faust et al[96]	6	NA	0	0	NA	LAM + HBIG5	43	0

¹80 000 IU (IV) in the first wk, then 1200 IU (IM) to aim for anti-HBs > 100 IU/L;

²IV for a median of 67 wk (LT before August 1998), then IM thereafter; 10 000 IU (IV) at LT, then 10 000 IU (IV) daily for 6 d (LT after August 1998), then IM thereafter;

³The HBV recurrence of patients with LT before August 1998;

⁴The HBV recurrence of patients with LT after August 1998;

⁵10 000 IU (IV) at LT, then 2000 IU (IV) for a median of 7 mo, then IM thereafter.